Gubra today announced the initiation of the first-in-human trial of GUB-UCN2, the company’s next mega program, with the first participant completing the first visit. The ambitious Phase 1/2a clinical trial sets the stage for exploring GUB-UCN2 across multiple indications and patient populations.Mar…
Gubra today announces that its partner Boehringer Ingelheim has initiated a Phase 2 clinical trial of BI 3034701, an investigational, potential first‑in‑class GLP‑1/GIP/NPY2 triple receptor agonist being developed for the treatment of overweight and obesity.Markus Rohrwild, CEO of Gubra, says:“The…
With reference to Section 30 of the Danish Capital Markets Act, Gubra has received notifications from The Capital Group Companies on June 26, 2026, and June 29, 2026, respectively, regarding changes to its shareholding and voting rights position in Gubra. Following these notifications, The Capital…
Gubra A/S (the "Company") completed a capital increase on 8 June 2026 as a result of the exercise of warrants granted in 2023.In accordance with section 32 of the Danish Capital Markets Act, the Company is required to disclose the total number of voting rights and shares in the event of changes.As…
